As Vice President Drug Discovery, Jane has led the pan-Trk inhibitor atopic dermatitis programme at BenevolentAI through preclinical development and phase I and is currently overseeing the phase II study. She directs a talented team of drug metabolism and pharmacokinetics (DMPK) and in vivo scientists who support drug programmes from early drug discovery to clinical development.
Jane has 28 years of experience in drug discovery and development, covering a range of therapeutic areas including pain and neurodegeneration. Before joining BenevolentAI in 2018, she worked for Parke-Davis, Pfizer, Millennium Pharmaceuticals, Cambridge Biotechnology, Biovitrum, Proximagen and Upsher-Smith. She has supported many drugs through candidate nomination and has made significant contributions to multifunctional project teams supporting phase I and phase II trials.